-Finafloxacin was shown to be genotoxic and clastogenic in vitro, with and without metabolic activation, and in vivo.
-General toxicity studies in rats have confirmed sperm toxicity following oral and intravenous dosing.
-At 500 mg/kg/day, males were completely infertile, presumably due to low sperm count and sperm immobility.
Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Magnesium | Magnesium can cause a decrease in the absorption of Finafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Finafloxacin. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Finafloxacin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Quinisocaine. |
| Cisatracurium | Finafloxacin may increase the neuromuscular blocking activities of Cisatracurium. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Finafloxacin is combined with Ambroxol. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Finafloxacin. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Finafloxacin is combined with Etrasimod. |